The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Eli Lilly (LLY) announced on Thursday that its newly approved weight loss pill Foundayo (orforglipron) will be available across U.S. retail pharmacies starting today, setting up a battle with Novo ...

Eli Lilly (LLY) faces a downgrade to Reduce from HSBC analyst Rajesh Kumar, who cut his price target from $1,070 to $850, citing overestimated obesity drug market size ($80B-$120B by 2032 versus ...

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...

Plug Power's stock has fallen nearly 95% in the past five years. Plug reported $5.5 million in gross profit in the fourth quarter of 2025. I've always had a healthy risk appetite when it comes to high ...

CHONGQING, CHINA - JANUARY 29: In this photo illustration, a smartphone displays the logo of Eli Lilly and Company (NYSE: LLY), a U.S.-based pharmaceutical company specializing in prescription ...

For most cars and trucks, gasoline and diesel engines follow the same four basic steps to make power: intake, to get a mixture of fuel and air into the cylinders; compression, to squeeze that mixture ...

What’s one of the best ways to upgrade your home for not much money at all? Add a few smart plugs to your outlets! They’ll make it easy to cut power to devices right from your phone, plus you can use ...

This holiday season, poison control experts are raising the alarm about the potential dangers of glow products and kids. Each Halloween, poison centers in the United States see a spike in the number ...

Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, ...